| License: Creative Commons Attribution 4.0 PDF - Published Version (8MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-463898
- DOI to cite this document:
- 10.5283/epub.46389
Hutchinson, James A. 
; Kronenberg, Katharina ; Riquelme, Paloma ; Wenzel, Jürgen J. ; Glehr, Gunther ; Schilling, Hannah-Lou ; Zeman, Florian ; Evert, Katja ; Schmiedel, Martin ; Mickler, Marion ; Drexler, Konstantin ; Bitterer, Florian ; Cordero, Laura ; Beyer, Lukas Philipp ; Bach, Christian ; Koestler, Josef ; Burkhardt, Ralph ; Schlitt, Hans J. ; Hellwig, Dirk ; Werner, Jens M. ; Spang, Rainer ; Schmidt, Barbara ; Geissler, Edward K. ; Haferkamp, Sebastian
; Kronenberg, Katharina ; Riquelme, Paloma ; Wenzel, Jürgen J. ; Glehr, Gunther ; Schilling, Hannah-Lou ; Zeman, Florian ; Evert, Katja ; Schmiedel, Martin ; Mickler, Marion ; Drexler, Konstantin ; Bitterer, Florian ; Cordero, Laura ; Beyer, Lukas Philipp ; Bach, Christian ; Koestler, Josef ; Burkhardt, Ralph ; Schlitt, Hans J. ; Hellwig, Dirk ; Werner, Jens M. ; Spang, Rainer ; Schmidt, Barbara ; Geissler, Edward K. ; Haferkamp, Sebastian 
Abstract
Treatment of advanced melanoma with combined PD-1/CTLA-4 blockade commonly causes serious immune-mediated complications. Here, we identify a subset of patients predisposed to immune checkpoint blockade-related hepatitis who are distinguished by chronic expansion of effector memory CD4(+) T cells (T-EM cells). Pre-therapy CD4(+) T-EM cell expansion occurs primarily during autumn or winter in ...
Owner only: item control page
Download Statistics